#BEGIN_DRUGCARD DB08058

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C21H21FN4O2

# Chemical_IUPAC_Name:
4-({3-[(1,4-diazepan-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one

# Chemical_Structure:
Not Available

# Creation_Date:
2010-09-15 15:28:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one

# HET_ID:
KU8

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C21H21FN4O2/c22-18-7-6-14(12-17(18)21(28)26-10-3-8-23-9-11-26)13-19-15-4-1-2-5-16(15)20(27)25-24-19/h1-2,4-7,12,23H,3,8-11,13H2,(H,25,27)

# InChI_Key:
InChIKey=HGEPGGJUGUMFHT-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
8064

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
380.4154

# Molecular_Weight_Mono:
380.164854141

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.69

# Predicted_LogS:
-3.8

# Predicted_Water_Solubility:
5.85e-02 g/l

# Primary_Accession_No:
DB08058

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
11291932

# PubChem_Substance_ID:
99444529

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCCNCC1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:26:22 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Nucleus. Cytoplasm, cytoskeleton, centrosome. Cytoplasm, cytoskeleton, centrosome, centriole

# Drug_Target_1_Chromosome_Location:
3

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Y16836

# Drug_Target_1_GenBank_ID_Protein:
29788060

# Drug_Target_1_GeneCard_ID:
PARP3

# Drug_Target_1_Gene_Name:
PARP3

# Drug_Target_1_Gene_Sequence:
>1623 bp
ATGTCCCTGCTTTTCTTGGCCATGGCTCCAAAGCCGAAGCCCTGGGTACAGACTGAGGGC
CCTGAGAAGAAGAAGGGCCGGCAGGCAGGAAGGGAGGAGGACCCCTTCCGCTCCACCGCT
GAGGCCCTCAAGGCCATACCCGCAGAGAAGCGCATAATCCGCGTGGATCCAACATGTCCA
CTCAGCAGCAACCCCGGGACCCAGGTGTATGAGGACTACAACTGCACCCTGAACCAGACC
AACATCGAGAACAACAACAACAAGTTCTACATCATCCAGCTGCTCCAAGACAGCAACCGC
TTCTTCACCTGCTGGAACCGCTGGGGCCGTGTGGGAGAGGTCGGCCAGTCAAAGATCAAC
CACTTCACAAGGCTAGAAGATGCAAAGAAGGACTTTGAGAAGAAATTTCGGGAAAAGACC
AAGAACAACTGGGCAGAGCGGGACCACTTTGTGTCTCACCCGGGCAAGTACACACTTATC
GAAGTACAGGCAGAGGATGAGGCCCAGGAAGCTGTGGTGAAGGTGGACAGAGGCCCAGTG
AGGACTGTGACTAAGCGGGTGCAGCCCTGCTCCCTGGACCCAGCCACGCAGAAGCTCATC
ACTAACATCTTCAGCAAGGAGATGTTCAAGAACACCATGGCCCTCATGGACCTGGATGTG
AAGAAGATGCCCCTGGGAAAGCTGAGCAAGCAACAGATTGCACGGGGTTTCGAGGCCTTG
GAGGCGCTGGAGGAGGCCCTGAAAGGCCCCACGGATGGTGGCCAAAGCCTGGAGGAGCTG
TCCTCACACTTTTACACCGTCATCCCGCACAACTTCGGCCACAGCCAGCCCCCGCCCATC
AATTCCCCTGAGCTTCTGCAGGCCAAGAAGGACATGCTGCTGGTGCTGGCGGACATCGAG
CTGGCCCAGGCCCTGCAGGCAGTCTCTGAGCAGGAGAAGACGGTGGAGGAGGTGCCACAC
CCCCTGGACCGAGACTACCAGCTTCTCAAGTGCCAGCTGCAGCTGCTAGACTCTGGAGCA
CCTGAGTACAAGGTGATACAGACCTACTTAGAACAGACTGGCAGCAACCACAGGTGCCCT
ACACTTCAACACATCTGGAAAGTAAACCAAGAAGGGGAGGAAGACAGATTCCAGGCCCAC
TCCAAACTGGGTAATCGGAAGCTGCTGTGGCATGGCACCAACATGGCCGTGGTGGCCGCC
ATCCTCACTAGTGGGCTCCGCATCATGCCACATTCTGGTGGGCGTGTTGGCAAGGGCATC
TACTTTGCCTCAGAGAACAGCAAGTCAGCTGGATATGTTATTGGCATGAAGTGTGGGGCC
CACCATGTCGGCTACATGTTCCTGGGTGAGGTGGCCCTGGGCAGAGAGCACCATATCAAC
ACGGACAACCCCAGCTTGAAGAGCCCACCTCCTGGCTTCGACAGTGTCATTGCCCGAGGC
CACACCGAGCCTGATCCGACCCAGGACACTGAGTTGGAGCTGGATGGCCAGCAAGTGGTG
GTGCCCCAGGGCCAGCCTGTGCCCTGCCCAGAGTTCAGCAGCTCCACATTCTCCCAGAGC
GAGTACCTCATCTACCAGGAGAGCCAGTGTCGCCTGCGCTACCTGCTGGAGGTCCACCTC
TGA

# Drug_Target_1_General_Function:
Involved in NAD+ ADP-ribosyltransferase activity

# Drug_Target_1_General_References:
10329013	Johansson M: A human poly(ADP-ribose) polymerase gene family (ADPRTL): cDNA cloning of two novel poly(ADP-ribose) polymerase homologues. Genomics. 1999 May 1;57(3):442-5.
12640039	Augustin A, Spenlehauer C, Dumond H, Menissier-De Murcia J, Piel M, Schmit AC, Apiou F, Vonesch JL, Kock M, Bornens M, De Murcia G: PARP-3 localizes preferentially to the daughter centriole and interferes with the G1/S cell cycle progression. J Cell Sci. 2003 Apr 15;116(Pt 8):1551-62.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
16641997	Muzny DM, Scherer SE, Kaul R, Wang J, Yu J, Sudbrak R, Buhay CJ, Chen R, Cree A, Ding Y, Dugan-Rocha S, Gill R, Gunaratne P, Harris RA, Hawes AC, Hernandez J, Hodgson AV, Hume J, Jackson A, Khan ZM, Kovar-Smith C, Lewis LR, Lozado RJ, Metzker ML, Milosavljevic A, Miner GR, Morgan MB, Nazareth LV, Scott G, Sodergren E, Song XZ, Steffen D, Wei S, Wheeler DA, Wright MW, Worley KC, Yuan Y, Zhang Z, Adams CQ, Ansari-Lari MA, Ayele M, Brown MJ, Chen G, Chen Z, Clendenning J, Clerc-Blankenburg KP, Chen R, Chen Z, Davis C, Delgado O, Dinh HH, Dong W, Draper H, Ernst S, Fu G, Gonzalez-Garay ML, Garcia DK, Gillett W, Gu J, Hao B, Haugen E, Havlak P, He X, Hennig S, Hu S, Huang W, Jackson LR, Jacob LS, Kelly SH, Kube M, Levy R, Li Z, Liu B, Liu J, Liu W, Lu J, Maheshwari M, Nguyen BV, Okwuonu GO, Palmeiri A, Pasternak S, Perez LM, Phelps KA, Plopper FJ, Qiang B, Raymond C, Rodriguez R, Saenphimmachak C, Santibanez J, Shen H, Shen Y, Subramanian S, Tabor PE, Verduzco D, Waldron L, Wang J, Wang J, Wang Q, Williams GA, Wong GK, Yao Z, Zhang J, Zhang X, Zhao G, Zhou J, Zhou Y, Nelson D, Lehrach H, Reinhardt R, Naylor SL, Yang H, Olson M, Weinstock G, Gibbs RA: The DNA sequence, annotation and analysis of human chromosome 3. Nature. 2006 Apr 27;440(7088):1194-8.
16924674	Rouleau M, McDonald D, Gagne P, Ouellet ME, Droit A, Hunter JM, Dutertre S, Prigent C, Hendzel MJ, Poirier GG: PARP-3 associates with polycomb group bodies and with components of the DNA damage repair machinery. J Cell Biochem. 2007 Feb 1;100(2):385-401.
17974005	Bechtel S, Rosenfelder H, Duda A, Schmidt CP, Ernst U, Wellenreuther R, Mehrle A, Schuster C, Bahr A, Blocker H, Heubner D, Hoerlein A, Michel G, Wedler H, Kohrer K, Ottenwalder B, Poustka A, Wiemann S, Schupp I: The full-ORF clone resource of the German cDNA Consortium. BMC Genomics. 2007 Oct 31;8:399.

# Drug_Target_1_HGNC_ID:
GNC:273

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6552

# Drug_Target_1_Locus:
3p21.31-p21.1

# Drug_Target_1_Molecular_Weight:
60069.7

# Drug_Target_1_Name:
Poly [ADP-ribose] polymerase 3

# Drug_Target_1_Number_of_Residues:
533

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00644	PARP
PF02877	PARP_reg
PF05406	WGR

# Drug_Target_1_Protein_Sequence:
>Poly [ADP-ribose] polymerase 3
MAPKPKPWVQTEGPEKKKGRQAGREEDPFRSTAEALKAIPAEKRIIRVDPTCPLSSNPGT
QVYEDYNCTLNQTNIENNNNKFYIIQLLQDSNRFFTCWNHWGRVGEVGQSKINHFTRLED
AKKDFEKKFREKTKNNWAERDHFVSHPGKYTLIEVQAEDEAQEAVVKVDRGPVRTVTKRV
QPCSLDPATQKLITNIFSKEMFKNTMALMDLDVKKMPLGKLSKQQIARGFEALEALEEAL
KGPTDGGQSLEELSSHFYTVIPHNFGHSQPPPINSPELLQAKKDMLLVLADIELAQALQA
VSEQEKTVEEVPHPLDRDYQLLKCQLQLLDSGAPEYKVIQTYLEQTGSNHRCPTLQHIWK
VNQEGEEDRFQAHSKLGNRKLLWHGTNMAVVAAILTSGLRIMPHSGGRVGKGIYFASENS
KSAGYVIGMKCGAHHVGYMFLGEVALGREHHINTDNPSLKSPPPGFDSVIARGHTEPDPT
QDTELELDGQQVVVPQGQPVPCPEFSSSTFSQSEYLIYQESQCRLRYLLEVHL

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. May link the DNA damage surveillance network to the mitotic fidelity checkpoint. Negatively influences the G1/S cell cycle progression without interfering with centrosome duplication. Binds DNA. May be involved in the regulation of PRC2 and PRC3 complex-dependent gene silencing

# Drug_Target_1_SwissProt_ID:
Q9Y6F1

# Drug_Target_1_SwissProt_Name:
PARP3_HUMAN

# Drug_Target_1_Synonyms:
IRT1
NAD(+) ADP-ribosyltransferase 3
PARP-3
Poly[ADP-ribose] synthetase 3
hPARP-3
pADPRT-3

# Drug_Target_1_Theoretical_pI:
6.73

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB08058
